Abstract:Objective: This study aimed to provide a basis for epidemic prevention and control measures as well as the management of re-positive personnel by analyzing and summarizing the characteristics of re-positive patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant infections discharged from a hospital in the Ningxia Hui Autonomous Region in 2021. Methods: This case-control study included a total of 45 patients with Delta variant infections diagnosed in the Fourth People's Hospital of the Ningxia Hui Autonomous Region between October 17 and November 28, 2021. Based on the nucleic acid test results post-discharge, the patients were dichotomized into re-positive and non-re-positive groups. Based on the time of the first re-positive test, the re-positive group was further divided into <7 and ≥7 days groups to compare their clinical characteristics and explore the possible influencing factors of this re-positivity. Results: Of the 45 total patients, 16 were re-positive (re-positivity rate: 35.6%), including four patients who were re-positive after 2 weeks (re-positivity rate: 8.8%). The median time of the first re-positive after discharge was 7 days (IQR: 14-3). The re-positive group was younger than the non-re-positive group (35 vs. 53, P < 0.05), had a higher proportion of patients who were not receiving antiviral therapy (56.2 vs. 17.2%, P < 0.05). The median CT value of nucleic acid in the re-positive group was considerably greater than that at admission (36.7 vs. 22.6 P < 0.05). The findings demonstrated that neutralizing antibody treatment significantly raised the average IgG antibody level in patients, particularly in those who had not received COVID-19 vaccine ( P < 0.05). The median lowest nucleic acid CT value of the ≥7 days group during the re-positive period and the immunoglobulin G (IgG) antibody level at discharge were lower than those in the <7 days group ( P < 0.05). When compared to the non-positive group, patients in the ≥7 days group had a higher median virus nucleic acid CT value (27.1 vs. 19.2, P < 0.05) and absolute number of lymphocytes at admission (1,360 vs. 952, P < 0.05), and a lower IgG antibody level at discharge ( P < 0.05). Conclusions: In conclusion, this study found that: (1) The re-positivity rate of SARS-CoV-2 Delta variant infection in this group was 35.6%, while the re-positivity rate was the same as that of the original strain 2 weeks after discharge (8.0%). (2) Young people, patients who did not use antiviral therapy or had low IgG antibody levels at discharge were more likely to have re-positive. And the CT value of nucleic acid at the time of initial infection was higher in re-positive group. We speculated that the higher the CT value of nucleic acid at the time of initial infection, the longer the intermittent shedding time of the virus. (3) Re-positive patients were asymptomatic. The median CT value of nucleic acid was > 35 at the re-positive time, and the close contacts were not detected as positive. The overall transmission risk of re-positive patients is low.

Clinical Characteristics, Cause Analysis and Infectivity of COVID‐19 Nucleic Acid Repositive Patients: A Literature Review

Analysis of the Causes and Countermeasures for Positive Recurrence of SARS CoV-2 RNA in Discharged Patients with COVID-19

[Follow-Up Testing of Viral Nucleic Acid in Discharged Patients with Moderate Type of 2019 Coronavirus Disease (COVID-19)].

Clinical Features of 81 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Jingzhou, China: A Descriptive Study

[Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19].

Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR

Prediction of Re-positivity for Coronavirus Nucleic Acid Among COVID-19 Patients in the Recovery Phase

Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China.

Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)

Recurrence of SARS-CoV-2 nucleic acid positive test in patients with COVID-19: a report of two cases

A comparative study of virus nucleic acid re-positive and non-re-positive patients infected with SARS-CoV-2 Delta variant strain in the Ningxia Hui Autonomous Region

The Clinical and Radiological Manifestations in Coronavirus Disease 2019 with Negative Nucleic Acid Results.

Clinical Course and Factors Associated with Viral RNA Shedding and Radiologic Resolution in Patients with COVID-19: a Retrospective Study

Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China

Retrospective analysis of the clinical features of outpatients with novel coronavirus in areas outside Wuhan, China

Repositive RT-PCR Test in Discharged COVID-19 Patients During Medical Isolation Observation.

Analysis of 2019 novel coronavirus infection and clinical characteristics of outpatients: An epidemiological study from a fever clinic in Wuhan, China

Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test

Viral RNA Level, Serum Antibody Responses, and Transmission Risk in Recovered COVID-19 Patients with Recurrent Positive SARS-CoV-2 RNA Test Results: a Population-Based Observational Cohort Study.

The characteristics of 527 discharged COVID-19 patients undergoing long-term follow-up in China

Clinical characteristics and potential factors for recurrence of positive SARS-CoV-2 RNA in convalescent patients: a retrospective cohort study